Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

诱导对庞贝病酶替代疗法的耐受性

基本信息

  • 批准号:
    8394488
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affecting heart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognosis for patients who have no circulating endogenous GAA (CRIM-negative Pompe disease) is markedly worse. The development of high titers of anti-rhGAA antibody and decreased effectiveness of replacement therapy often result in the death of CRIM-negative Pompe infants in the first year of life. We propose to evaluate the effect of natural tolerance-inducing peptides, Tregitopes, in a murine model of CRIM-negative Pompe disease. Tregitopes cause the expansion and activation of regulatory T cells, suppress inflammatory T cell responses and reduce humoral immune responses to co-administered proteins. In the plan outlined here, we will test Tregitopes co-delivered with GAA epitopes, as a tolerance-inducing (1) Prophylactic therapy or (2) Therapeutic treatment of ongoing anti-GAA immune responses. We will evaluate an AAV-vector for Tregitope-GAA epitope delivery. The program will establish proof-of-principle that will lead to further studies in Phase II. Even a moderate degree of success with the protocol developed here may improve the lives of CRIM-negative babies and could be applied to other enzyme replacement therapies to which ADA have been induced. An experienced team will carry out the program, including Richard Garman who has extensive experience with the Pompe mouse model, Annie De Groot, a well-established T cell immunologist, Leslie Cousens, Ph.D. expert in Tregitope immunomodulation studies, Tim Messitt, Ph.D. molecular biologist and Federico Mingozzi Ph.D., AAV expert, who will co-develop the Tregitope-GAA AAV vector. PUBLIC HEALTH RELEVANCE: We propose to evaluate the effect of natural tolerance-inducing peptides, Tregitopes (T regulatory cell epitopes), to induce long-lasting and specific tolerance to enzyme replacement therapy in a murine model of Pompe disease. Proof of principle for Tregitopes in treating anti-drug antibody responses in the context of Pompe disease will have immediate impact on the field of enzyme replacement therapy and could lead to accelerated adaptation of Tregitope therapy in the treatment of these children.
描述(由申请方提供):诱导庞贝氏症对酶替代疗法的耐受性庞贝氏症是一种溶酶体贮积症,由酸性α-葡萄糖苷酶(GAA)缺陷引起,导致影响心脏和骨骼肌的糖原蓄积。重组人(rh)GAA的酶替代疗法可挽救庞贝氏症儿童的生命。没有循环内源性GAA(CRIM阴性庞贝氏症)的患者的预后明显更差。高滴度抗rhGAA抗体的产生和替代治疗有效性的降低通常导致CRIM阴性庞贝氏症婴儿在出生后第一年死亡。我们建议评估天然耐受诱导肽Tregitopes在CRIM阴性庞贝氏症小鼠模型中的作用。Tregitope引起调节性T细胞的扩增和活化,抑制炎性T细胞应答并降低对共同施用的蛋白质的体液免疫应答。在这里概述的计划中,我们将测试与GAA表位共同递送的Tregitopes,作为正在进行的抗GAA免疫应答的耐受诱导(1)预防性治疗或(2)治疗性治疗。我们将评估用于Tregitope-GAA表位递送的AAV载体。该计划将建立原理证明,这将导致在第二阶段的进一步研究。即使是在这里开发的协议的中等程度的成功可能会改善CRIM阴性婴儿的生活,并可以应用于其他酶替代疗法,ADA已被诱导。一个经验丰富的团队将执行该计划,包括在Pompe小鼠模型方面拥有丰富经验的Richard Garman,成熟的T细胞免疫学家Annie De Groot,Leslie Cousens博士。Tregitope免疫调节研究专家Tim Messitt博士分子生物学家和费德里科·明戈齐博士,AAV专家,他将共同开发Tregitope-GAA AAV载体。 公共卫生关系:我们建议评估天然耐受诱导肽Tregitopes(T调节细胞表位)在庞贝氏症小鼠模型中诱导对酶替代疗法的持久和特异性耐受的效果。Tregitopes在庞贝氏症背景下治疗抗药抗体反应的原理证明将对酶替代疗法领域产生直接影响,并可能导致Tregitope疗法在这些儿童治疗中的加速适应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anne Searls DeGroot其他文献

Anne Searls DeGroot的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anne Searls DeGroot', 18)}}的其他基金

ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability
ISPRI-HCP:CHO 蛋白杂质免疫原性风险预测,用于改进生物仿制药产品开发和评估产品互换性
  • 批准号:
    10620080
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
  • 批准号:
    10216952
  • 财政年份:
    2017
  • 资助金额:
    $ 30万
  • 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
  • 批准号:
    9362529
  • 财政年份:
    2017
  • 资助金额:
    $ 30万
  • 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
  • 批准号:
    9978692
  • 财政年份:
    2017
  • 资助金额:
    $ 30万
  • 项目类别:
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
基于新型抗原特异性免疫调节 Tregitope 的疗法可解决格雷夫斯病的自身免疫发病机制
  • 批准号:
    9410057
  • 财政年份:
    2017
  • 资助金额:
    $ 30万
  • 项目类别:
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
针对隐形 H7N9 流感的无佐剂 VLP 疫苗的开发
  • 批准号:
    9304958
  • 财政年份:
    2016
  • 资助金额:
    $ 30万
  • 项目类别:
TRIAD Pilot Projects Core
TRIAD 试点项目核心
  • 批准号:
    8378749
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
A 型血友病联合因子 VIII 替代和耐受治疗
  • 批准号:
    8508305
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Multi-intracellular Pathogen Epitope-based Vaccine
基于多细胞内病原体表位的疫苗
  • 批准号:
    8378738
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
A 型血友病联合因子 VIII 替代和耐受治疗
  • 批准号:
    8313747
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了